CamAPS Liberty®: the dawn of fully closed-loop technology
The world’s first fully closed-loop feature will become available within the existing CamAPS® FX app.
In a pioneering move for type 1 diabetes care, CamDiab’s new CamAPS Liberty feature will support users when daily demands feel particularly challenging by pausing the need to count carbohydrates or deliver meal boluses.
First unveiled today at the Advanced Technologies & Treatments for Diabetes (ATTD) Congress 2026, this landmark innovation is designed to boost the mental energy, wellbeing and quality of life of CamAPS FX users, while also ensuring effective glucose management.
This groundbreaking, fully closed-loop feature will become accessible to all CamAPS FX users, pending market-specific approvals and availability.
Prof. Roman Hovorka, Founder of CamDiab, said: ‘CamAPS Liberty represents a huge milestone for the diabetes community, marking the dawn of commercially available fully closed-loop technology. Our focus has always been on people, not just innovation.
By embedding it into our CamAPS FX app, CamDiab is ensuring this progress remains accessible, equitable and truly centred around the needs of those living with type 1 diabetes. This feature provides additional support beyond glycaemic outcomes, when people need it most.’
Support beyond the numbers
How does CamAPS Liberty work?
When activated, the user will enable a fully closed-loop mode in which they will not be required to count their carbohydrates or deliver a pre-meal insulin bolus. CamAPS Liberty is powered by a more proactive version of the CamAPS® algorithm, designed to anticipate and respond to glucose changes while operating within established safety boundaries.
All existing CamAPS FX features will remain available, including Boost, Ease-off, Add Meal and manual insulin boluses. This ensures maximum flexibility and allows users to optimise their therapy according to individual needs.
Automated data sharing via Companion, Glooko®, mylife Cloud and the CamAPS two-week PDF report continues uninterrupted, providing transparency and visibility for carers and diabetes care teams to support therapy decision-making.
The feature offers an option for people who may benefit from reducing the cognitive and emotional load of diabetes management at key moments in their lifelong journey with type 1 diabetes. This may include periods of stress, travel, busy work or school commitments, or other life events. The feature is designed to complement, not replace, an individual’s existing diabetes management plan.
CamDiab announced the feature was granted approval by CamDiab’s notified body in January 2026.
CamAPS Liberty has not been studied in pregnancy or in children under 13 years of age and is therefore not recommended for use in these populations. CamDiab is working with its partners to make this landmark innovation available to both mylife Loop AID users (Android and iOS) and Dana CamAPS FX users (Android); pending market-specific approvals and availability.
About CamDiab Ltd
CamDiab is a digital health and personalised medicine company focused on the design, development, and commercialisation of its world-leading, interoperable CamAPS FX closed-loop app. CamAPS FX is designed to use an adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycaemic management. Since its founding in 2019, its mission has been to help people with type 1 diabetes and their families live better lives.
Find out more at www.camdiab.com, or connect with us on Facebook, Instagram, LinkedIn, X, and YouTube.